# Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal Adenocarcinoma

> **NCT03995017** · PHASE1,PHASE2 · UNKNOWN · sponsor: **University of Kansas Medical Center** · enrollment: 34 (actual)

## Conditions studied

- Esophagus Cancer, Adenocarcinoma
- Stomach Cancer, Adenocarcinoma

## Interventions

- **DRUG:** Rucaparib
- **DRUG:** Ramucirumab
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT03995017
- **Lead sponsor:** University of Kansas Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01-09
- **Primary completion:** 2022-10-19
- **Final completion:** 2024-12
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2023-02-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03995017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03995017, "Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal Adenocarcinoma". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT03995017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*